209 related articles for article (PubMed ID: 35822433)
21. Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.
Overby A; Duval L; Ladekarl M; Laursen BE; Donskov F
Clin Genitourin Cancer; 2019 Feb; 17(1):e32-e37. PubMed ID: 30268423
[TBL] [Abstract][Full Text] [Related]
22. Biomarkers of systemic inflammation provide additional prognostic stratification in cancers of unknown primary.
Harvey S; Stares M; Scott JA; Thottiyil TJV; Conway AM; Haigh R; Brown J; Knowles G; Dasgupta S; Shiu KK; Mitchell C; Barrie C; Cook N; Clive S
Cancer Med; 2024 Feb; 13(3):e6988. PubMed ID: 38404120
[TBL] [Abstract][Full Text] [Related]
23. Clinical features of cancer with unknown primary site (clinical features, treatment, prognosis of cancer with unknown primary site).
Yang H; He F; Xu W; Cao Z
BMC Cancer; 2022 Dec; 22(1):1372. PubMed ID: 36587212
[TBL] [Abstract][Full Text] [Related]
24. Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy.
Kodaira M; Takahashi S; Yamada S; Ueda K; Mishima Y; Takeuchi K; Yamamoto N; Ishikawa Y; Yokoyama M; Saotome T; Terui Y; Hatake K
Ann Oncol; 2010 Jun; 21(6):1163-1167. PubMed ID: 20019088
[TBL] [Abstract][Full Text] [Related]
25. p16 expression in carcinoma of unknown primary: diagnostic indicator and prognostic marker.
Vent J; Haidle B; Wedemeyer I; Huebbers C; Siefer O; Semrau R; Preuss SF; Klussmann J
Head Neck; 2013 Nov; 35(11):1521-6. PubMed ID: 23345170
[TBL] [Abstract][Full Text] [Related]
26. Risk factors and predictors for tumor site origin in metastatic adenocarcinoma of unknown primary site.
Li X; Shao Y; Sheng L; Zhu J; Wang Z; Guo K; Sun L
Cancer Med; 2021 Feb; 10(3):974-988. PubMed ID: 33405390
[TBL] [Abstract][Full Text] [Related]
27. Cancer of Unknown Primary Presenting as Bone-Predominant or Lymph Node-Only Disease: A Clinicopathologic Portrait.
Huey RW; Smaglo BG; Estrella JS; Matamoros A; Overman MJ; Varadhachary GR; Raghav KPS
Oncologist; 2021 Apr; 26(4):e650-e657. PubMed ID: 33524217
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis and management of carcinoma of unknown primary in the head and neck.
Issing WJ; Taleban B; Tauber S
Eur Arch Otorhinolaryngol; 2003 Sep; 260(8):436-43. PubMed ID: 12684829
[TBL] [Abstract][Full Text] [Related]
29. Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan.
Yakushiji S; Ando M; Yonemori K; Kohno T; Shimizu C; Katsumata N; Fujiwara Y
Int J Clin Oncol; 2006 Dec; 11(6):421-5. PubMed ID: 17180509
[TBL] [Abstract][Full Text] [Related]
30. Hepatic metastases from carcinomas of unknown primary site.
Pouessel D; Thezenas S; Culine S; Becht C; Senesse P; Ychou M
Gastroenterol Clin Biol; 2005 Dec; 29(12):1224-32. PubMed ID: 16518276
[TBL] [Abstract][Full Text] [Related]
31. Metastases with definitive pathological diagnosis but no detectable primary tumor: A surveillance epidemiology and end results-based study.
Tao L; Yu H; Dong Y; Tian G; Ren Z; Li D
Cancer Med; 2019 Oct; 8(13):5872-5880. PubMed ID: 31407505
[TBL] [Abstract][Full Text] [Related]
32. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary tumor site.
Hainsworth JD; Greco FA
Semin Oncol; 1993 Jun; 20(3):279-86. PubMed ID: 8503024
[TBL] [Abstract][Full Text] [Related]
33. [Metastases of unknown origin--principles of diagnosis and treatment].
Petrović D; Muzikravić L; Jovanović D
Med Pregl; 2007; 60(1-2):29-36. PubMed ID: 17853708
[TBL] [Abstract][Full Text] [Related]
34. [Cancer of unknown primary site origin--advances in diagnosis and therapy].
Plot L; Dovrish Z; Hadari R; Weisenberg N; Zehavi T; Nisenbaum B; Amital H
Harefuah; 2008 Apr; 147(4):294-8, 376, 375. PubMed ID: 18686808
[TBL] [Abstract][Full Text] [Related]
35. Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer.
Riihimäki M; Thomsen H; Hemminki A; Sundquist K; Hemminki K
BMC Cancer; 2013 Jan; 13():36. PubMed ID: 23356713
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes of patients diagnosed with cancer of unknown primary or malignancy of undefined primary origin who were referred to a regional cancer center.
Ando M; Honda K; Hosoda W; Matsubara Y; Kumanishi R; Nakazawa T; Ogata T; Nakata A; Kodama H; Masuishi T; Narita Y; Taniguchi H; Kadowaki S; Muro K
Int J Clin Oncol; 2023 May; 28(5):644-653. PubMed ID: 36899286
[TBL] [Abstract][Full Text] [Related]
37. Site-specific cancer deaths in cancer of unknown primary diagnosed with lymph node metastasis may reveal hidden primaries.
Hemminki K; Bevier M; Sundquist J; Hemminki A
Int J Cancer; 2013 Feb; 132(4):944-50. PubMed ID: 22730111
[TBL] [Abstract][Full Text] [Related]
38. Renal Cell Carcinoma Presenting as Carcinoma of Unknown Primary Site: Recognition of a Treatable Patient Subset.
Greco FA; Hainsworth JD
Clin Genitourin Cancer; 2018 Aug; 16(4):e893-e898. PubMed ID: 29610002
[TBL] [Abstract][Full Text] [Related]
39. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
40. Carcinoma of unknown primary (CUP): an update for histopathologists.
Beauchamp K; Moran B; O'Brien T; Brennan D; Crown J; Sheahan K; Cotter MB
Cancer Metastasis Rev; 2023 Dec; 42(4):1189-1200. PubMed ID: 37394540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
